China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
CAMBRIDGE, Mass., Feb. 17, 2016 -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EST on Thursday, February 25, 2016, to provide a business update and to discuss its fourth quarter 2015 financial and operating results.
To listen to the live webcast of the call, please visit the "Investors" section of the Company's website at www.aegerion.com. Individuals may also participate in the call via telephone by dialing (866) 516-3002 or (760) 298-5082. Interested parties unable to join the live call may access an archived version of the webcast on Aegerion's website for up to 30 days following the call.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy, Associate Director, IR & PR 857-242-5024
